PRD Therapeutics
Latest round
- Series A
Last raised
- Sep 2023
Total raised
- $8.9M
Investors
- 5
About PRD Therapeutics
a. PRD Therapeutics, researches and develops new lipid metabolism regulators that are effective for rare diseases that cause lipid metabolism abnormalities. In September 2023, PRD Therapeutics, Inc. As of September 2023, Renji Hosoda is the CEO of the company. The company’s product line includes PRD001, an oral lipid-lowering drug for HoFH, which is a rare dyslipidemia with few treatments. PRD001 uses a new mechanism to regulate the blood cholesterol levels of patients.
Who invested in PRD Therapeutics
5 investors across 1 round
See all investors in PRD Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 1, 2023
Amount
$8.9M
Investors
Questions about PRD Therapeutics
Who invested in PRD Therapeutics?
PRD Therapeutics has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PRD Therapeutics raised?
PRD Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did PRD Therapeutics last raise money?
PRD Therapeutics's most recent round on record is a Series A, in Sep 2023.
What does PRD Therapeutics do?
PRD Therapeutics is a biotechnology company.
Where is PRD Therapeutics headquartered?
PRD Therapeutics is headquartered in Tokyo, Japan.
Which VCs invest in companies like PRD Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at PRD Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like PRD Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.